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Abstract
Background:  Giant  hepatic  hemangiomas  (GHHs)  are  those  that  are  larger  than  4  cm  in  size.
Aims: The  aim  of  this  study  was  to  describe  GHH  clinical  ﬁndings,  their  risk  factors,  diag-
nostic approach  and  management,  and  to  compare  these  data  with  those  of  conventional
hemangiomas.
Methods:  We  performed  a  retrospective  analysis  of  patients  diagnosed  with  hemangiomas,
whether by  imaging  studies  or  histopathology,  at  our  hospital  within  the  time  frame  of  1990-
2008. The  medical  records  of  each  patient  were  reviewed  to  obtain  clinical  and  surgical  data.
Results: Of  the  57  patients  with  liver  hemangioma,  41  (72%)  were  women  and  32  (56%)  had
GHH. Liver  hemangioma  median  size  was  4.49  cm.  In  regard  to  the  patients  with  GHH,  31.2%
were asymptomatic  and  when  symptoms  presented,  pain  was  the  most  common.  Both  symptoms
and oral  contraceptive  exposure  were  more  common  in  the  GHH  patients.  Nine  patients  with
GHH underwent  surgery:  2  open  biopsies  due  to  diagnostic  uncertainty,  one  enucleation,  and
6 resections. Please cite this article as: Moctezuma-Velázquez C, López-Arce G, Martínez-Rodríguez LA, Escalona-Huerta C, Chapa-Ibargüengoitia M,
Torre A. Hemangioma hepático gigante versus hemangioma hepático convencional: características clínicas, factores de riesgo y manejo.
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Conclusions:  GHHs  are  more  prevalent  in  women  and  when  symptomatic,  pain  is  the  most  fre-
quent complaint.  Diagnosis  is  usually  made  through  imaging  studies,  but  when  there  is  diagnostic
doubt, surgical  exploration  is  sometimes  needed.  Oral  contraceptive  use  is  most  likely  more
of a  risk  factor  for  GHH  than  for  conventional  hemangioma,  but  this  association  needs  to  be
studied further.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.  All
rights reserved.
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Hemangioma  hepático  gigante  versus  hemangioma  hepático  convencional:
características  clínicas,  factores  de  riesgo  y  manejo
Resumen
Antecedentes:  Los  hemangiomas  hepáticos  gigantes  (HHG)  son  aquellos  con  un  taman˜o  superior
a 4  cm.
Objetivo:  El  objetivo  de  este  estudio  fue  describir  los  hallazgos  clínicos  del  HHG,  sus  factores  de
riesgo, el  abordaje  diagnóstico  y  el  manejo,  y  comparar  esta  información  con  la  del  hemangioma
convencional.
Métodos:  Se  realizó  un  análisis  retrospectivo  del  periodo  1990-2008  de  pacientes  con  diagnós-
tico, sea  por  imagen  o  histopatología,  de  hemangioma  hepático  atendidos  en  nuestro  hospital.
De cada  paciente  se  revisó  su  expediente  para  extraer  información  médica  y/o  quirúrgica.
Resultados:  De  57  pacientes  con  hemangioma  hepático,  41  (72%)  eran  mujeres  y  32  (56%)  tenían
un HHG.  La  mediana  de  taman˜o  fue  de  4.49  cm.  Con  respecto  a  los  HHG,  el  31.2%  estaban  asin-
tomáticos; el  síntoma  más  común  fue  dolor.  Tanto  los  síntomas  como  el  uso  de  anticonceptivos
orales fueron  más  comunes  en  pacientes  con  HHG.  Nueve  pacientes  con  HHC  fueron  sometidos
a cirugía:  2  biopsias  abiertas  por  duda  diagnóstica,  una  enucleación  y  6  resecciones.
Conclusiones:  Los  HHG  son  más  prevalentes  en  mujeres  y,  cuando  son  sintomáticos,  el  dolor  es
la manifestación  más  frecuente.  El  diagnóstico  habitualmente  se  hace  por  imagen,  pero  a  veces
se requiere  abordaje  quirúrgico  por  duda  diagnóstica.  El  uso  de  anticonceptivos  orales  es  pro-
bablemente  un  factor  de  riesgo  de  más  peso  para  el  HHG  que  para  el  hemangioma  convencional;
esta asociación  necesita  ser  estudiada  más  a  fondo.
© 2014  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Cntroduction
epatic  hemangiomas  (HHs)  are  the  most  common  benign
epatic  tumors,  with  an  estimated  prevalence  of  7%  in
utopsies  and  1-20%  in  the  general  population.1--4 They  are
ore  common  in  women,  probably  as  a  result  of  an  inﬂu-
nce  of  female  sex  hormones  on  their  growth.5 Giant  hepatic
emangiomas  (GHHs),  deﬁned  as  those  HHs  greater  than
 cm  in  size,  represent  10%  of  all  HHs.
HHs  are  usually  asymptomatic  and  found  incidentally.6
ymptoms  have  been  reported  in  up  to  40%  of  patients  with
 GHH  in  some  case  series,  mainly  abdominal  pain,  but  also
ymptoms  related  to  a  mass  effect  such  as  early  satiety,  nau-
ea,  vomiting,  cholestasis,  or  even  cough.7--10 Less  common
anifestations  are  chylous  ascites,  hemoperitoneum  due
o  spontaneous  rupture,  and  Kasabach-Merritt  syndrome,
n  which  the  HH  is  associated  with  thrombocytopenia  and
ntravascular  coagulation.6,11--13
HHs  are  suspected  when  ultrasonography  shows  nod-
les  with  homogeneous  hyperechogenicity,  but  additional
maging  tests,  usually  triphasic  computed  tomography  (TCT)
r  magnetic  resonance  imaging  (MRI),  are  required  to
a
s
Sonﬁrm  the  diagnosis  due  to  the  lack  of  speciﬁcity  of
ltrasonographic  ﬁndings.  TCT  typically  reveals  progressive
nhancement  during  the  arterial  phase  in  a  centripetal  fash-
on.  MRI  shows  a  low  signal  intensity  on  T1-weighted  images,
igh  signal  intensity  on  T2-weighted  sequences,  and  an
nward  enhancement  after  gadolinium  administration  can
e  seen.14 Tc-99m-labeled  red  blood  cell  single  emission
hoton  computed  tomography  may  be  helpful  when  there
s  diagnostic  uncertainty;  it  has  sensitivity,  speciﬁcity  and
ccuracy  of  97%,  83%,  and  96%,  respectively.15 Positron  emis-
ion  tomography  is  useful  to  differentiate  heterogeneous  HH
rom  angiosarcomas.16 The  differential  diagnosis  includes
ngiomatosis,  metastases,  hematic  cyst,  hepatic  peliosis,
nd  hepatocellular  carcinoma,  among  others.
Treatment  options  of  HH,  including  GHH,  are  obser-
ation,  enucleation,  hepatic  resection,  and  transcatheter
rterial  embolization;  recently,  enhanced  radiofrequency
blation  has  been  used  to  treat  GHH,  with  good  results.17
linical  observation  is  recommended  for  most  patients,
ctive  treatment  should  be  reserved  for  patients  with
evere  symptoms  or  disease-associated  complications.18
urgical  indications  include  abdominal  pain,  mass  effect,
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gFigure  1  Magnetic  resonance  image  of  a  GHH  in  the  right  lobe
low signal  intensity.  B)  The  mass  is  homogeneous  and  hyperinte
Kasabach-Merritt  syndrome,  increased  hemangioma  size
during  follow-up,  and  equivocal  results  during  radio-
logical  evaluation  leading  to  uncertainty  of  diagnosis.
Regarding  surgery,  there  are  2  different  strategies:  enu-
cleation  and  hepatic  resection.  The  most  important
factors  associated  with  surgical  complications  are  tumor
size  and  the  presence  of  symptoms.19 Enucleation  is
a  better  option  because  resection  is  associated  with  a
longer  hospital  stay,  greater  blood  loss,  and  transfusion
requirements.20--23 Preoperative  percutaneous  transcatheter
arterial  embolization  is  useful  in  reducing  the  risk  of
intraoperative  bleeding.24 Embolization  with  bleomycin  and
lipiodol  is  a  useful  alternative  when  HHs  are  unﬁt  for
surgery.25
The  aim  of  this  study  was  to  describe  the  experience
regarding  diagnosis  and  management  of  giant  hemangiomas
w
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Figure  2  Gadolinium-magnetic  resonance  image  of  a  GHH  in  th
enhancement across  the  simple  (A),  arterial  (B),  portal  (C),  and  lateT1-weighted  image  that  shows  a  homogeneous  focal  mass  with
n  the  T2-weighted  image.
t  our  hospital,  and  compare  these  data  with  those  of  con-
entional  hemangiomas.
ethods
e  performed  a  retrospective  analysis  of  patients  with  HH
t  our  hospital  within  the  time  frame  of  January  1,  1990
nd  November  31,  2008.  We  made  an  electronic  search
egarding  outpatient  and  inpatient  hospital  records  look-
ng  for  the  diagnosis  of  hemangioma  and/or  benign  hepatic
umor,  which  corresponded  to  the  D  18.0  and  D  13.4  cate-
ories  of  the  CIE  10,  respectively.  We  included  all  patients
ith  GHH  and  HH,  and  diagnosis  was  based  on  the  presence
f  conclusive  imaging  ﬁndings  on  TCT  or  MRI  (peripheral
odular  enhancement  in  the  early  phase  followed  by  cen-
ripetal  enhancement  during  the  late  phase)  (ﬁgs.  1-4)  or  on
e  right  lobe.  Images  show  a  progressive  centripetal  nodular
 (D)  phases.
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tion  and  non-parametric  statistical  analyses  were  employed.
Categorical  variables  were  described  using  frequencies  andigure  3  Computed  tomography  scan  of  a  GHH  in  the  left  lobe
nhancement  across  the  simple  (A),  arterial  (B),  portal  (C),  and
he  histopathology  report.  Medical  records  were  reviewed
or  each  patient  to  obtain  demographic,  clinical,  radiologi-
al,  and  laboratory  information,  evolution,  and  treatment;
f  surgery  was  performed,  data  regarding  the  type  of  surgery,
uration,  complications,  and  transfusion  requirements  were
ecorded.  Pain  due  to  HH  was  deﬁned  as  persistent  pain  in
he  upper  right  abdomen  that  could  not  be  better  explained
y  an  alternative  diagnosis,  including  irritable  bowel  syn-
rome.
ltrasound
 Siemens  Sonoline  Antares,  Phillips,  or  General  Electric
ogiq  9  US  device  was  used,  with  convex  probes  from  1
o  7 MHz.  The  exploration  protocol  at  our  institution  begins
ith  the  left  hepatic  lobe  and  then  the  right  hepatic  lobe,
ooking  for  focal  lesions;  if  a  focal  lesion  is  found,  it  has
o  be  demonstrated  in  2  planes,  measured,  and  then  color
oppler  is  applied  to  assess  vascularity.
riphasic  Computed  Tomography
 16  or  a  64-slice  multidetector  CT  (Somatom,  Sensation  16
r  64;  Siemens  Munich,  Germany)  was  used;  images  were
btained  with  a  section  thickness  of  3-5  mm  and  a  recon-
truction  interval  of  2-2.5  mm.  All  cases  were  analyzed  on
 workstation  with  the  capacity  to  produce  coronal  refor-
atted  images.  All  patients  received  both  intravenous  and
ral  contrast.  For  intravenous  contrast,  120  ml  of  Conray
Mallinckrodt  Baker  Inc.,  St  Louis  Missouri,  USA)  was  given
5  s prior  to  performing  the  scan;  for  oral  contrast,  40  ml
p
u
b
Finistration  of  contrast  shows  a  progressive  centripetal  nodular
 (D)  phases.
f  Ioditrast  M60  (Justesa  Imagen  Mexicana)  were  diluted
n  1,000  ml  of  water  and  given  to  all  patients  orally  one
our  prior  to  computed  tomography.  All  TCT  images  were
nalyzed  by  at  least  2  certiﬁed  radiologists.
agnetic  resonance  imaging
agnetic  resonance  imaging  (MRI)  was  performed  on  a  1.5  T
ystem  (Signa  Excite  HD,  GE  Healthcare,  Milwaukee,  USA),
sing  a  variety  of  software  upgrades  that  evolved  during
he  study  period.  Standard  liver  imaging  sequences  included
1-weighted  In-phase  and  Opposed-phase  gradient  echo
nd  T2-weighted  fast  spin  echo  sequences.  T1-weighted
maging  was  repeated  after  contrast  material  administra-
ion  during  hepatic  arterial  (19-25  s),  portal  (40-45  s),
enous  (60-65  s)  and  delayed  (3-5  min)  phases.  Patients
eceived  Gadopentate  Dimeglumine  (Gd-DTPA  [Magnevist,
ayer  Schering  Pharma])  at  a  mean  dose  of  0.1  mmol/kg  of
ody  weight,  a  unique  bolus  at  a  1.5  - 2  ml/s  rate,  followed
y  a  saline  ﬂush  (mean  volume  20  ml).
tatistical  Analysis
xcept  for  age,  all  variables  had  a  non-normal  distribu-ercentages  and  continuous  variables  were  summarized
sing  the  median  and  interquartile  range.  Comparisons
etween  groups  were  made  with  the  chi-square  test  or
isher’s  exact  test.  Data  analysis  was  done  with  SPSS  v17.
Giant  hepatic  hemangioma  versus  conventional  hepatic  hemangioma:  Clinical  ﬁndings  233
Figure  4  Magnetic  resonance  image  of  a  HH  in  the  right  lobe.  A)  T2-weighted  image  shows  a  focal  hyperintense  mass.  B)  The
hemangioma is  hypointense  on  T1-weighted  images.  C,  D,  and  E)  Images  show  a  progressive  centripetal  nodular  enhancement  across
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wthe arterial,  portal,  and  late  phases.
Results
A  total  of  57  patients  with  HH  were  evaluated  and  72%  were
women.  The  mean  age  was  46.7  ±  11.5  years  and  it  was
not  signiﬁcantly  different  in  patients  with  or  without  GHH.
Thirty-two  patients  had  a  GHH.  Of  the  96  lesions  included  in
the  analysis,  32  were  GHH  and  64  were  conventional  heman-
giomas.  Thirteen  patients  with  GHH  had  an  additional  one
or  more  conventional  hemangiomas,  and  7  patients  with-
out  GHH  had  more  than  one  lesion.  The  median  size  of
the  hemangiomas  was  4.49  cm,  ranging  from  1-11  cm.  The
median  number  of  lesions  was  1.68  hemangiomas  for  each
patient,  ranging  from  1  to  10.  GHH  distribution  was  as  fol-
lows:  right  lobe  in  18  patients  (56%),  left  lobe  in  7  patients
(22%),  and  both  lobes  in  7  patients  (22%).  Absence  of  alco-
hol  consumption  was  more  common  in  patients  without  GHH
W
3
r
(p  =  0.003,  OR  3.8  CI  2.7-5.4),  while  previous  or  present
ontraceptive  use  was  more  common  in  patients  with  GHH
p  =  0.001,  OR  1.45  CI  1.29-1.7).
Ten  patients  with  GHH  (31.2%)  were  asymptomatic  and
t  was  an  incidental  ﬁnding;  in  the  rest  of  them,  pain  was
he  most  common  symptom  and  was  found  in  11  patients
34.4%),  followed  by  3  patients  (9.4%)  with  an  increase
n  abdominal  perimeter.  One  patient  developed  cholangitis
ecause  the  GHH  compressed  the  common  bile  duct.  Table  1
hows  the  diagnosis  that  led  to  the  discovery  of  the  GHH  in
he  cases  in  which  it  was  an  incidental  ﬁnding.  Symptoms
ere  more  common  in  patients  with  a GHH  (p  =  00.003).
hen  we  divided  the  HHs  into  those  bigger  and  smaller  than
 cm,  rather  than  4  cm,  there  was  no  signiﬁcant  difference  in
elation  to  the  presence  of  symptoms  between  the  2  groups
p  =  0.09).
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Table  1  Diagnosis  which  led  to  the  incidental  ﬁnding  of
giant hepatic  hemangiomas.
Cause  of  detection  n
Peptic  ulcer  disease  (NSAID*-related) 1
Abnormal  liver  tests  secondary  to  drugs  1
Acute  cholecystitis  2
Viral hepatitis  1
Urinary  tract  infection  1
Cholangitis  1
Fever  of  unknown  origin  1
Hysterectomy  complicated  with  peritonitis 1
2
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Table  3  Characteristics  of  the  surgical  procedures  (n  =  9).
Duration,  median  (range)  600  min  (120-640)
Time between  symptom  onset
and  diagnosis,  median
(range)
6  m  (1-60)
Type  of  surgery,  n  (%)
Enucleation  1  (11)
Resection  6  (67)
Open biopsy  2  (22)
Preoperative  hemoglobin,
median  (range)
14.2  g/dl  (12-17)
Postoperative  hemoglobin,
median  (range)
12.5  g/dl  (10-14)
Hemoglobin  loss,  median  1.8  g/dl
Patients  transfused,  n  (%)  6  (66)
Blood units  transfused,  units
(range)
2.5  (1-9)
Complications  related
to  surgery,  n  (%)
3  (33)
r
t
f
m
D
T
T
sIrritable  bowel  syndrome 1
NSAID: nonsteroidal anti-inﬂammatory drug.
Diagnosis  of  GHH  was  initially  made  with  ultrasound  in
9  patients  and  with  TCT  in  the  other  3.  Diagnosis  was  con-
rmed  with  TCT  or  MRI  in  all  cases  except  for  one  patient  in
hom  hepatic  resection  was  performed  after  the  diagnostic
ltrasound  was  made.  Liver  function  tests  were  normal  in
ll  patients.
Surveillance  was  indicated  in  23  (72%)  of  the  patients
ith  GHH.  Three  of  them  had  pain,  but  did  not  undergo
urgery;  the  pain  was  consistent  with  a  functional  disorder
nd  disappeared  with  antispasmodics  in  2  of  those  patients,
nd  one  did  not  accept  the  surgical  procedure.  Surgery  was
erformed  in  the  other  9  patients  (28%).  Two  of  them  were
symptomatic  and  the  indication  was  to  perform  an  open
iopsy  because  of  diagnostic  uncertainty  after  a  thorough
adiological  evaluation;  in  both  cases  the  radiologists  could
ot  exclude  a  metastasis  of  an  unknown  primary.  Table  2
hows  the  characteristics  of  the  patients  assigned  to  surveil-
ance  and  those  treated  with  surgery.  Three  patients  had
urgery-related  complications.  One  of  them  developed  a
epatic  hematoma  leading  to  hypovolemic  shock,  and  the
ther  2  had  right  pleural  effusion,  both  of  which  were
Table  2  Characteristics  of  patients  according  to
treatment.
Surveillance
n  =  23
Surgery
n  =  9
Women,  n  (%)  18  (78)  7  (78)
Age (years),  mean  46  48
Clinical  manifestations,  n  (%)
None  8  (35)  2  (22)
Pain 3  (13)  8  (89)
Increased
abdominal
perimeter
1  (4)  2  (22)
Cholangitis  0  (0)  1  (11)
Hemangioma  size
(cm),  median
6  9
Number  of
hemangiomas,
median
1  1
Follow-up
(months),
median
80.1  66.5
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aEstimated  bleeding,  ml  (range)  500  (105-8,000)
esolved  with  a  chest  tube  and  negative  pressure.  No  mor-
ality  related  to  surgery  was  observed  in  the  long-term
ollow-up  (66.5  ±  58  months).  Table  3  shows  important  infor-
ation  regarding  the  surgical  procedures.
iscussion
hirty-two  patients  in  our  study  presented  with  GHH.
wenty-three  of  them  were  candidates  for  surveillance
trategy  and  the  remaining  9  underwent  surgical  treatment.
ost  of  our  patients  were  women  in  their  mid-forties,  which
oncurred  with  previous  studies.  Ten  patients  were  asymp-
omatic  and  GHH  was  diagnosed  incidentally,  as  a  result
f  an  imaging  study  indicated  for  another  reason.  In  symp-
omatic  patients,  the  most  frequent  symptom  was  pain.  It  is
mportant  to  mention  that  persistent  pain  in  the  upper  right
bdomen  that  could  not  be  better  explained  by  any  other
iagnosis  was  attributed  to  the  GHH.  However,  the  pain  was
onspeciﬁc  and  because  there  is  no  gold  standard  to  diag-
ose  hemangioma-induced  pain,  there  is  a  possibility  that  in
ome  cases  this  symptom  could  be  due  to  another  pathology.
Most  authors  consider  GHHs  as  those  larger  than  4  cm,
hile  others  deﬁne  them  as  larger  than  5  cm.  When  we  ana-
yzed  symptom  presentation  of  the  HHs  that  were  bigger  and
maller  than  3  cm  we  did  not  ﬁnd  a  signiﬁcant  difference,
o  we  feel  the  best  cutoff  point  is  4  cm.  In  contrast  to  other
ase  series,  GHHs  represented  a  greater  proportion  of  the
Hs  at  our  institute.  A  possible  explanation  to  this  is  that
ur  hospital  is  a  referral  center  and  smaller  hemangiomas
re  usually  diagnosed  and/or  treated  elsewhere.
Compared  to  conventional  HH,  GHHs  were  more  com-
on  in  female  patients  who  had  been  previously  exposed
o  oral  contraceptives  and  in  patients  who  said  they  had
o  prior  or  present  alcohol  consumption.  Concerning  these
isk  factors,  neither  alcohol  consumption  nor  oral  contra-
eptive  use  was  quantiﬁed  (for  example,  number  of  years
sing  oral  contraceptives  or  drinking  pattern)  in  order  to
nalyze  this  association  more  carefully.  In  some  studies,  oral
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Table  4  Comparison  with  other  case  series.
Description  Mean  age
(years)
Female:male
ratio
Mean  size
(cm)
Symptomatic
hemangiomas
(%)
Surgical  rate
(%)
Type  of
surgical
approach  (%)
Surgical
indication
(%)
Symptomatic
hemangiomas
(%)
Surgical
morbidity
(%)
Surgical
mortality
(%)
Our  case
series
57  patients
with  HH;  32
(56%)  with
GHH
46.7a 2.6:1a 4.4a 68.8b 28b Enucleation
(11)
Resection  (67)
Open  biopsy
(22)
Abdominal
pain  (33)
Uncertain
diagnosis
(22)
68.8b 33  0
Etemadi A,
et  al.29
198  patients
with  HH;  36
(18.2%)  with
GHH
44.3a 2:1a 5.2a -  7  Resection  100 Abdominal
pain  (44)
-  -  -
Schnelldorfer
T, et  al.18
289  GHH 51  2.7:1  8.4  30  19  Resection:  60
Enucleation:
40
Abdominal
pain  (52)
Uncertain
diagnosis
(3.7)
30  14  0
Hamaloglu
E, et  al.20
22  patients
with  GHH
who  u
nderwent
surgery
46  21:1  9  95  100  Resection:  54
Enucleation:
46
Abdominal
pain  (77)
Uncertain
diagnosis
(13.6)
95  14  0
GHH: Giant hepatic hemangioma; HH: Hepatic hemangioma.
a Including all HH.
b Including only GHH.
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236  
ontraceptive  use  has  been  found  to  be  a  risk  factor  for
HH,  but  in  others  this  association  has  not  been  encoun-
ered,  while  alcohol  abuse  has  been  proposed  as  a  risk
actor  for  HH  in  another  case  series.  We  know  that  HHs  are
ore  common  in  women,  suggesting  an  effect  of  female  sex
ormones,  but  this  relation  is  unclear.  For  example,  there
re  cases  of  hemangiomas  that  have  grown  during  preg-
ancy  and  that  were  negative  for  estrogen  and  progesterone
eceptors.5,26--29
Even  though  enucleation  is  associated  with  less  morbid-
ty,  hepatic  resection  was  the  procedure  of  choice  in  all  the
atients,  except  for  one.20--22 This  can  be  explained  by
he  fact  that  treatment  decisions  often  reﬂect  the
xperience  of  the  surgeon.  Six  patients  required  blood  trans-
usions;  one  of  them  developed  hypovolemic  shock  and  had
o  be  transferred  to  the  intensive  care  unit.  Mayor  mor-
idity  related  to  the  surgical  procedure  and  transfusion
ate  was  slightly  increased  when  compared  with  other  case
eries.19,20,23,30 Patients  in  the  surveillance  group  developed
o  symptoms  during  follow-up,  supporting  the  benign  course
f  this  entity,  regardless  of  hemangioma  size.18 Table  4  com-
ares  our  results  with  other  case  series  in  relation  to  mean
ge,  size,  number  of  symptomatic  hemangiomas,  surgical
ate,  and  type  of  approach,  as  well  as  morbidity  and  mor-
ality  associated  with  surgery.
Our  study  has  several  limitations  and  one  of  them  is  its
etrospective  design.  Imaging  tools  for  increasing  sensitiv-
ty  and  speciﬁcity  of  the  radiological  evaluation  of  hepatic
esions  have  evolved  since  1990;  therefore,  we  have  no
ay  of  knowing  if  surgery  could  have  been  spared  in  the
 cases  of  diagnostic  uncertainty  after  radiological  evalu-
tion,  had  they  been  reevaluated  with  these  more  recent
ools.15 In  addition,  we  could  not  compare  enucleation  vs
epatic  resection  because  only  one  patient  was  assigned  to
he  former.  Moreover,  as  previously  mentioned,  oral  contra-
eptive  use  and  alcohol  consumption  were  not  objectively
easured.  Finally,  we  cannot  exclude  referral  bias,  the  fact
hat  the  majority  of  HHs  were  GHHs  and  that  most  of  them
ere  symptomatic,  could  be  the  reason  they  were  referred
o  our  hospital.
In  conclusion,  GHHs  are  more  frequent  in  women,  many
f  them  are  asymptomatic,  and  when  they  are  symptomatic,
ain  is  the  most  frequent  complaint.  As  imaging  tech-
iques  have  evolved,  diagnosis  is  usually  made  in  terms  of
adiological  studies.  However,  in  a  minority  of  cases,  diag-
ostic  uncertainty  remains  and  surgical  exploration  may  be
eeded.  Oral  contraceptive  use  is  probably  more  a  risk  fac-
or  for  the  development  of  GHH  than  for  conventional  HH,
hile  alcohol  consumption  seems  to  be  less  frequent  in  GHH
atients.  Nevertheless,  these  associations  need  to  be  stud-
ed  further.
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